# Cannabinoid Clinical Trials: Mental Health Evidence Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/ > **Published:** 2026-04-28T17:39:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:54:34-04:00 > **Clinical Summary:** Explore cannabinoid efficacy and safety for mental disorders and substance use disorders through systematic review evidence-based clinical analysis. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchSafetyNeurologyCBD Why This Matters Clinicians need this evidence synthesis to make informed decisions about cannabinoid recommendations for patients with specific conditions like insomnia and Tourette’s syndrome, where conventional treatments may be inadequate or poorly tolerated. The finding that cannabinoids may help with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder itself is particularly relevant for addiction medicine specialists developing harm reduction and treatment strategies. However, the limited evidence base documented in this review highlights the need for cautious prescribing and continued monitoring until larger, higher-quality trials establish optimal dosing and long-term safety profiles. Clinical Summary A [systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) of cannabinoid efficacy and safety in mental health and substance use disorders found limited but promising evidence supporting cannabinoid treatment for cannabis use disorder, insomnia, tics or Tourette’s syndrome, and autism spectrum disorder. The review indicates that while cannabinoids show potential in these specific conditions, the overall evidence base remains modest and heterogeneous, with many studies employing small sample sizes or methodological limitations that restrict definitive clinical recommendations. Safety concerns were noted alongside efficacy findings, suggesting that clinicians should carefully weigh benefits against risks when considering cannabinoid therapies for their patients. The authors highlight significant gaps in the literature, particularly the need for larger, well-controlled randomized trials to establish optimal dosing, long-term safety profiles, and patient populations most likely to benefit. For practicing clinicians, this summary underscores that while cannabinoids may have a role in specific psychiatric and neurological conditions, current evidence does not yet support broad clinical adoption, and individual patient assessment combined with shared decision-making remains essential before initiating cannabinoid-based treatment. Dr. Caplan’s Take “What we’re seeing in the literature is that cannabinoids have legitimate therapeutic potential for specific, narrow indications like cannabis use disorder and severe insomnia, but the evidence remains thin for broader psychiatric applications, and clinicians need to resist the temptation to treat every anxious or depressed patient with cannabis when we have more established alternatives with better safety profiles.” Clinical Perspective While emerging evidence suggests cannabinoids may have therapeutic potential for specific conditions including cannabis use disorder, insomnia, and tic disorders, clinicians should approach these findings with appropriate caution given the heterogeneity of available studies, variable dosing regimens, and limited long-term safety data in psychiatric populations. The paradox that cannabinoids show promise for cannabis use disorder while cannabis itself remains a risk factor for psychosis and cognitive impairment in vulnerable patients underscores the complexity of cannabinoid therapeutics and the importance of understanding specific cannabinoid profiles, patient phenotypes, and dosing strategies. Confounders such as publication bias, small sample sizes, and the difficulty isolating cannabinoid effects from placebo responses in psychiatric trials further complicate clinical interpretation. For practitioners considering cannabinoid-based interventions, current evidence supports a cautious, individualized approach that involves careful baseline psychiatric and substance use assessment, discussion of 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+The+efficacy+and+safety+of+cannabinoids+for+the+treatment+of+mental+disorders+and+substance+...+%40drcaplan&url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanpsy%2Farticle%2FPIIS2215-0366%2826%2900015-5%2Ffulltext)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanpsy%2Farticle%2FPIIS2215-0366%2826%2900015-5%2Ffulltext)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+The+efficacy+and+safety+of+cannabinoids+for+the+treatment+of+mental+disorders+and+substance+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanpsy%2Farticle%2FPIIS2215-0366%2826%2900015-5%2Ffulltext)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [LEGACY CANNABIS BRAND ANNOUNCES NATIONWIDE PRODUCT EXPANSION](https://cedclinic.com/cannabinol-sleep-aid-nationwide-product-expansion/) - Cannabis May Help Treat Fatty Liver Disease – HepMag.com - [Cannabis for pets? Maryland vets could soon recommend it | WBAL Baltimore News](https://cedclinic.com/how-cannabis-transforms-animal-medicine-maryland-vets/) 📰 Source: [https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00015-5/fulltext](https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00015-5/fulltext) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Clinical Trials: Mental Health Evidence Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) A detailed review of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) assessing cannabinoids in mental health treatment, summarizing current evidence and research gaps. [Read the Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Cannabinoid Clinical Trials for Mental & Substance Disorders Explore clinical trial data on cannabinoids for mental and substance use disorders, highlighting therapeutic potential and safety considerations. Explore Clinical Trials [Cannabinoids in Mental Health Treatment: A Systematic Review and Meta-Analysis](https://cedclinic.com/cannabinoids-mental-health-substance-use-disorders-review/) Systematic review and meta-analysis of cannabinoids in mental health treatment, providing evidence-based insights for clinicians. [View Meta-Analysis](https://cedclinic.com/cannabinoids-mental-health-substance-use-disorders-review/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).